Researchers have discovered a mechanism lung cancer cells use when spreading into the body to form metastases. They have also found a factor controlling the spreading of several different cancer types. The common feature in both findings is that they explain the lethal ability of cancer cells to “start running” and spread from the original tumor to other parts of the body.

A new study reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone — the two most prominent sites of lung cancer relapse.

A new study by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone the two most prominent sites of lung cancer relapse. The study will be published online in the journal Cell on July 2.

AstraZeneca announced that it has received a licence by the European Medicines Agency (EMEA) for its oral targeted anti-cancer drug, gefitinib, for EGFR (epidermal growth factor receptor-tyrosine kinase) activating mutation positive patients with Non Small Cell Lung Cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for 80% of all lung cancer cases.

As scientists continue to decode the human genome and the information becomes publicly available, private companies that offer online genetic testing are multiplying. Scientists at the National Institutes of Health were concerned that perhaps these tests posed a risk.

Any cancer - a growth, lump, tumor - of the colon and the rectum is a type of colorectal cancer. Colorectal cancer is also known as bowel cancer. The UK National Health Service says colorectal cancer is the most common cancer globally today. However, the World Health Organization says it is the second most common cancer, after lung cancer.

Researchers, on a quest to find lung cancer stem cells, have developed a unique model to allow further investigation into the cells that many believe may be at the root of all lung cancers.

Helix BioPharma Corp. (TSX, FSE: HBP) announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp.

Researchers at UCLA’s Jonsson Comprehensive Cancer Center, on a quest to find lung cancer stem cells, have developed a unique model to allow further investigation into the cells that many believe may be at the root of all lung cancers.

The risk of lung cancer increases for those smokers who have a tendency to binge drinking.